TABLE 3.
Virus | Characterization ofa:
|
||||||
---|---|---|---|---|---|---|---|
21H8 (IP) | Site II, 30AA5-40DC2 (IP, IF, and NT) | Site III
|
Site a, 9B4 (IP and NT) | Linear site, 17D2 (IP) | P75-Fc (IP and NT) | ||
41BC2 (IP and NT) | 50AD1 (IF and NT) | ||||||
CVS | + | + | + | + | + | + | + |
F318V | + | + | + | + | + | + | − |
F318S | + | + | + | + | + | + | − |
H352Y | + | + | + | + | + | + | − |
H352R | + | + | + | + | + | + | − |
Mutants were characterized for their interaction with anti-RVG MAbs by immunoprecipitation (IP), immunofluorescence (IF), or neutralization (NT).